Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death due to lack of treatment options. Most of the therapeutic strategies in current use (surgery, transplantation, irradiation or chemotherapy) are either palliative or only benefit a small number of patients. This review focuses on the development of innovative gene therapy strategies employed in the treatment of HCC that have progressed in recent years, towards becoming a treatment to compliment current therapies.
No takes yet. Share an insight, caveat, or question.
Paula Yeng Po Lam (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: